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Probiotics are defined as live micro-organisms that when administered in adequate
amounts confer a health benefit on the host. Among their pleiotropic effects, inhibition of
pathogen colonization at the mucosal surface as well as modulation of immune responses
are widely recognized as the principal biological activities of probiotic bacteria. In recent
times, the immune effects of probiotics have led to their application as vaccine adjuvants,
offering a novel strategy for enhancing the efficacy of current vaccines. Such an approach
is particularly relevant in regions where infectious disease burden is greatest and where
access to complete vaccination programs is limited. In this study, we report the effects
of the probiotic, Lactobacillus rhamnosus GG (LGG) on immune responses to tetanus,
Haemophilus influenzae type b (Hib) and pneumococcal conjugate (PCV7) vaccines in
infants. This study was conducted as part of a larger clinical trial assessing the impact of
maternal LGG supplementation in preventing the development of atopic eczema in infants
at high-risk for developing allergic disease. Maternal LGG supplementation was associated
with reduced antibody responses against tetanus, Hib, and pneumococcal serotypes con-
tained in PCV7 (N =31) compared to placebo treatment (N =30) but not total IgG levels.
Maternal LGG supplementation was also associated with a trend to increased number of
tetanus toxoid-specific T regulatory in the peripheral blood compared to placebo-treated
infants. These findings suggest that maternal LGG supplementation may not be benefi-
cial in terms of improving vaccine-specific immunity in infants. Further clinical studies are
needed to confirm these findings. As probiotic immune effects can be species/strain spe-
cific, our findings do not exclude the potential use of other probiotic bacteria to modulate
infant immune responses to vaccines.
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INTRODUCTION
The success of vaccination as a public health measure is best
illustrated by the substantial reductions in rates of infectious dis-
eases such as smallpox, polio, tetanus, and diphtheria following
the introduction of these vaccines in the early part of the nine-
teenth century (1). Since that time, vaccination remains one of
the most cost-effective health care intervention tools, and global
vaccination rates are above 80% in most developed countries (2).
The efficacy of vaccines is the result of a combination of factors
that include the effectiveness of the specific vaccine, the type of
adjuvant included in the vaccine and the achievement of vaccine
delivery (completion of recommended schedule) which is in turn
influenced by cost and feasibility of route of administration. The
term adjuvant comes from the latin “adjuvare” meaning “to help.”
Adjuvants are critical components of vaccines as they help the
immune system respond to the vaccine by several proposed mech-
anisms such as immunomodulation, cytokine regulation as well as
depot formation, which allows for sustained release at the site of
injection to maintain a continual source of immune stimulation
(3, 4).
Despite these achievements, there are a number of significant
challenges that remain. In particular, many children (and adults)
living in developing countries still die from vaccine-preventable
diseases such as tetanus, pneumococcal disease and rotavirus (5).
In the last 10 years, international organizations such as the GAVI
Alliance have made a profound impact on child health by improv-
ing access and delivery of these life-saving vaccines (6). Continued
effort is required to reduce the burden of infectious disease in
these settings and it is likely that the combination of increased
vaccine coverage as well as the development of novel vaccines and
adjuvants will be critical in reducing vaccine-preventable disease
globally.
The identification of novel vaccine adjuvants have been the sub-
ject of intense scientific research over many decades. Particularly
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important is their activity at the mucosal surface as well as their
ability to target both systemic and mucosal immunity, since most
infections occur via the mucosal surface (7). Protection by current
vaccines typically relies on recommended schedules that consist
of multiple dosing over the first 1–2 years of life. In resource-
limited settings, this represents significant challenges in terms of
cost and delivery. Adjuvants demonstrated to enhance immuno-
logical activity may allow for reduced vaccine dosing in these
regions and could be given earlier to protect infants against initial
colonization by pathogenic bacteria such as the pneumococcus.
The mechanisms of action of current human approved adjuvants
such as alum are controversial and have several limitations (8).
Many candidate adjuvants have been studied, but only very few
are approved for human use due to toxicity issues or a lack of
immunogenicity. Therefore, novel adjuvants that can overcome
these limitations are required. In recent times, the use of probi-
otic bacteria as immunomodulators has been investigated owing
to their pleiotropic biological effects. Probiotics are defined as“live
micro-organisms which when administered in adequate amounts,
confer a health benefit on the host” (9). The immunomodulatory
activities of probiotic bacteria make them potentially useful can-
didates as novel adjuvants for human vaccines that require further
research.
The most well characterized probiotics include those of the
Lactobacillus or Bifidobacterium species (10). These probiotics
have been shown to be safe in humans and animals in a num-
ber of studies. In particular, the probiotic Lactobacillus rhamnosus
GG (LGG) is reported to have a number of immune-modulating
effects, including cytokine responses, enhancing protective IgG
and IgA levels as well upregulating certain immune cell popu-
lations (11, 12). Moreover, LGG has been reported in a limited
number of studies to enhance certain vaccine-specific responses
(13, 14). Maternal intervention has been one approach to inves-
tigate the potential beneficial effects of probiotics such as LGG
on increasing early-life protection. In this study, we examined the
capacity for the probiotic LGG to enhance immune responses in
infants that were part of a larger phase II maternal LGG interven-
tion study for the prevention of allergic disease. Responses to the
common childhood vaccines tetanus, Haemophilus influenzae type
b and the pneumococcal conjugate vaccine (PCV7) were measured
as well as total IgG levels.
MATERIALS AND METHODS
STUDY SAMPLES
Plasma and peripheral blood mononuclear cells (PBMCs) samples
used in this study were collected from infants of mothers (n= 250)
that were part of a randomized controlled trial of prenatal LGG
for the prevention of eczema (Probiotic Eczema Prevention Study
registered with Cochrane Skin Group www.nottingham.ac.uk/
ongoingskintrials Trial No. 36) (15). This study was approved
by both the Royal Children’s Hospital and Mercy Hospital for
Women Research Ethics Committees and all participants gave
written informed consent. Mothers were randomized to receive
1.8× 1010 colony forming units LGG (American Type Culture
Collection 53103; Dicofarm, Italy) each morning from 36 weeks
gestation until delivery, or maltodextrin placebo. At 12 months of
age, blood samples (5–10 ml) were collected from infants and in
this study, the adjuvant effect of LGG was examined in plasma
and PBMC samples collected from infants whose mothers were
given LGG (N = 31) or placebo (N = 30). Participants, clinical
trial and laboratory staff were blinded to treatment allocations
and immunological assays throughout the study.
MEASUREMENT OF TETANUS AND Hib ANTIBODY RESPONSES
FOLLOWING VACCINATION
Plasma concentrations of IgG antibodies against H. influenzae
type b polysaccharide were measured by ELISA using a previ-
ously published method (16). 96-well microtiter plates were coated
with H. influenzae type b polysaccharide conjugated to human
serum albumin (BEI Resources, Manassas, VA, USA) overnight at
4°C. The standard anti-Hib polysaccharide serum (Lot 1983, FDA,
USA), control anti-Hib human reference serum (NIBSC, UK) and
infant samples were added to coated ELISA plates and incubated
for 2 h. Horseradish peroxidase-conjugated sheep anti-human IgG
(Chemicon, Australia) was used as the detection antibody and a
3.3′, 5.5′-tetramethylbenzidine (TMB) substrate solution (KPL,
Gaithersburg, MD, USA) was used for detection. Optical densi-
ties were read on a microplate reader at 450 nm (reference fil-
ter 630 nm) and converted to µg/ml using KC Junior software
(Bio-Tek Instruments Inc., USA).
A commercially available ELISA kit (Genzyme Virotech GmbH,
Rüsselsheim, Germany) was used to quantitate plasma concentra-
tions of IgG against tetanus toxoid (TT).
MEASUREMENT OF PNEUMOCOCCAL ANTIBODY RESPONSE
FOLLOWING PCV7
Plasma levels of pneumococcal serotype-specific IgG were mea-
sured using a modified WHO-recommended method (17). Briefly,
serotype-specific pneumococcal polysaccharides [American Type
Culture Collection (ATCC), USA] were diluted in PBS and
adsorbed (coated) onto medium-binding plates (Greiner, Ger-
many) at 37°C for 5 h and then stored at 4°C overnight (O/N).
Plates were blocked with phosphate-buffered saline containing
10% (v/v) Fetal Calf Serum (PBS/FCS) and incubated at 37°C
for 1 h. Plasma and control samples were diluted 1:100 in a
double absorption buffer of PBS/FCS containing cell-wall poly-
saccharide (CPS; 10µg/ml) and serotype 22F (30µg/ml) and
incubated overnight at 4°C. A standard serum 89-SF (Food
and Drug Administration, USA) was pre-absorbed with CPS
only. Following washing of ELISA plates with PBS containing
0.05% (v/v) Tween 20 (PBS-T), serial dilutions of the pre-
absorbed 89-SF standard, control, and plasma samples were added
and incubated at 37°C for 2 h. Plates were washed with PBS-
T and a horseradish peroxidase-conjugated sheep anti-human
IgG (Chemicon, Australia) was added and incubated at 37°C
for 2 h followed by a further wash step with PBS-T. The reac-
tion was developed by incubation with a TMB substrate solu-
tion for 9 min and stopped by the addition of 1 M phosphoric
acid. Absorbance at 450 nm (630 nm reference filter) was mea-
sured using a microplate reader (Bio-Tek, USA). Pneumococ-
cal serotype-specific IgG concentrations for each sample were
derived from the 89-SF standard values and expressed in micro-
gram per milliliter using KC Junior software (Bio-Tek Instruments
Inc., USA).
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MEASUREMENT OF TOTAL IgG LEVELS IN SERUM
96-well medium-binding microtiter plates (Greiner, Germany)
were coated with 50 ng/ml of unlabeled human IgG (Southern
Biotechnology, USA) diluted in carbonate-bicarbonate buffer, pH
9.6 overnight at 4°C. Plates were then blocked with 5% (w/v)
skim milk powder in PBS-T for 1 h at RT followed by incuba-
tion of standards, serum samples, and controls for 2 h at RT. Level
of IgG in serum samples were detected using a 1:5000 dilution
of a sheep anti-human IgG-HRP reagent for a further 2 h at RT
and developed with a TMB substrate solution for 7 min at RT.
Reactions were stopped with the addition of 1 M phosphoric acid
and absorbance at 450 nm (630 nm reference filter) was measured
using a microplate reader (Bio-Tek, USA). The amount of total
IgG in serum samples were derived from the standard curve (in-
house control) and expressed in microgram per deciliter using KC
Junior software (Bio-Tek Instruments Inc., USA).
PERIPHERAL BLOOD MONONUCLEAR CELL ISOLATION AND CULTURE
Blood samples (5–10 ml) were collected from infants at 12 months
of age into preservative-free sodium heparin tubes. PBMCs were
separated from heparinized blood by density gradient centrifuga-
tion (Ficoll-Paque,Sweden) within 8 h of collection and rate frozen
at a concentration of 8–10× 106 cells/ml. PBMCs were thawed
rapidly at 37°C, washed in RPMI-1640 medium (Gibco, Grand
Island, NY, USA) and re-suspended at 1× 106 cells/ml for cul-
ture. Thawed PBMC were cultured in AIM-V serum free medium
(Gibco, Grand Island, NY, USA) supplemented with 4× 10−5 M
of 2-Mercapethanol (2-ME; Gibco, Grand Island, NY, USA) and
stimulated with TT (1µg/ml) or left in medium alone (with 2-ME;
unstimulated) for 6 days at 37°C in 5% CO2 in air.
ENUMERATION OF Treg IN PBMCs BY FLOW CYTOMETRY
After 6 days of culture, PBMCs were centrifuged at 600 g for
10 min at room temperature and supernatants removed. Cell pel-
lets were stained with fluorochrome-conjugated monoclonal anti-
bodies in 50µl staining volumes. CD3-allophycocyanin (APC),
CD4-peridinin chlorophyll protein (PerCP), CD25-phycoerythrin
(PE)-Cy7 (BD Bioscience, San Jose, CA, USA) and forkhead box
P3 (FoxP3)-PE (e-Bioscience, San Diego, CA, USA) were used to
identify CD25hiFoxP3hi T cell populations in PBMCs. The pro-
liferative response to TT was evaluated in 6 day cultures using
the cell tracking dye Carboxyfluorescein Diacetate Succinimidyl
Ester (CFSE; 0.1µM). Non-proliferating cells were identified as
CFSEhi and proliferating cells as CFSElo. Cells were washed once
with PBS and incubated with fluorochrome-labeled antibodies
or isotype controls in 50µl staining volumes for 30 min. For
intracellular staining, cells were subsequently permeabilized, fixed,
and stained with FoxP3-PE antibody or isotype control accord-
ing to the manufacturer’s instructions (e-Bioscience). Data were
acquired on a 4-color LSR II (BD, San Jose, CA, USA) and analyzed
with FACSDiva v4.1 software using well-defined gating strategies.
A minimum of 100,000 events were acquired in the lymphocyte
gate.
STATISTICAL ANALYSIS
The Student’s t -test was used to analyze normally distributed con-
tinuous data, and Mann–Whitney U -test was used for skewed
data. Data were presented as either geometric means with 95%
confidence intervals (CI), or median with interquartile range
(IQR) depending on the distribution. Frequency data was ana-
lyzed using the Fisher’s exact test. A p-value<0.05 was considered
statistically significant. Analyses were performed using GraphPad
PrismVersion 6 (GraphPad Software Inc.,CA,USA). Linear regres-
sion models (or logistic regression when the outcome was binary)
were used to adjust for potential confounders in Stata (StataCorp
LP, USA) including the presence of IgE-associated eczema ever
or at 12 months of age, atopy, and yogurt intake, as there were
trends toward significance for these variables between the LGG
and placebo groups.
RESULTS
STUDY COHORT
A summary of the characteristics of study participants is pre-
sented in Table 1. No significant differences were found although
there were trends toward a higher proportion of infants who were
atopic (46.6 vs. 23.3%; p= 0.07) and had reported IgE-associated
eczema (33.3 vs. 13.3%; p= 0.07) in the LGG group compared to
placebo (Table 1). No differences were found for any of the other
characteristics.
MATERNAL LGG SUPPLEMENTATION WAS ASSOCIATED WITH
REDUCED VACCINE-SPECIFIC BUT NOT TOTAL IgG RESPONSES IN
INFANTS
We examined the impact of maternal LGG supplementation on
the antibody response to a number of childhood vaccines in
Table 1 | Characteristics of study participants.
Characteristic LGG (n=30)a Placebo (n=30)
Infant eczema ever 43.3% 40%
Infant eczema 12 months 40% 23.3%
Infant IgE-eczema ever 33.3%* 13.3%
Infant IgE-eczema 12 months 33.3%* 13.3%
Atopy 46.6%** 23.3%
Paternal eczema 22.6% 21.4%
Maternal eczema 45.2% 51.7%
Sibling eczema 86.4% 60.9%
Antibiotics during pregnancy 29% 23.3%
Daily yogurt intake during
pregnancy (g/week), median
(range)
200 (0–1400)*** 600 (0–1400)
Maternal tertiary education 83.3% 72.4%
Household smoker 13.3% 13.8%
Other children present in
household
66.7% 58.6%
Infant sex – female 33.3% 38.7%
Gestation (weeks), median (range) 39.5 (35.4–41.5) 39.5 (37.4–41.5)
Birthweight (g), median (range) 3300 (2700–3975) 3550 (2770–5020)
Cesarean delivery 25.8% 32.1%
Duration of breastfeeding in first
year (months), median (range)
8.5 (0–12) 9 (6–12)
aCharacteristics unavailable for one infant.
*p=0.07; **p=0.06; ***p=0.05 between LGG and probiotic groups.
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FIGURE 1 | Serotype-specific IgG levels (GMC±95% CI) for infants in
the LGG (N =31) or Placebo (N =30) groups following PCV7
immunization. *p<0.05 comparing LGG and Placebo treatment.
infants at 12 months of age. There were significant differences in
the unadjusted GMC for serotype-specific IgG to PCV7 serotypes
4 (p= 0.027), 6B (p= 0.040), 18C (p= 0.032), 19F (p= 0.041),
and 23F (p= 0.019) between the LGG and placebo-treated groups
following immunization (Figure 1). Lower serotype-specific IgG
levels were observed across all serotypes, with fold decreases of
between 0.58 and 0.83 for serotypes 23F and 14, respectively in
the LGG group relative to the placebo group. After adjustment
for eczema status, a significant difference still remained for each
of these serotypes while adjustment for atopy resulted in the
serotype-specific IgG response for 9 V also becoming significant
(p= 0.040; Table A1A in Appendix). Yogurt intake did not affect
the PCV7 response after adjustment (Table A1B in Appendix).
In addition, there was a significantly lower proportion of infants
with serotype-specific IgG antibody titers>0.35µg/ml (indicative
of a protective response post-PCV7) in the LGG group compared
to placebo for four of the seven serotypes in PCV7 (serotypes
4, 9V, 18C, and 23F, all p< 0.05; Figure 2A). However, using
a cut off of 1.0µg/ml of serotype-specific IgG, there were no
differences between infants of LGG and placebo-treated moth-
ers (although there was a trend for serotype 19F; p= 0.058)
(Figure 2B). Adjustments for eczema status, atopy,or yogurt intake
did not alter the conclusions reached about the impact on this
response (Tables A2A,B and A3A,B in Appendix).
Plasma levels of anti-tetanus toxoid IgG were also significantly
reduced in infants of mothers treated with LGG compared to
infants of placebo-treated mothers, with unadjusted GMCs of 0.96
and 0.51 IU/ml (p= 0.042) in the LGG and placebo treatment
groups respectively, representing a 1.9-fold difference between
groups (Figure 3A). After adjustment for each of the potential
confounders, the observed association weakened but remained
statistically significant (p< 0.05) for all variables other than IgE-
associated eczema at 12 months of age (p= 0.052; Tables A1A,B
FIGURE 2 | Proportion of infants with a serotype-specific IgG
levels≥0.35µg/ml (A) or≥1.0µg/ml (B) for infants in the LGG (N = 31)
or Placebo (N =30) groups following PCV7 immunization. *p<0.05
comparing LGG and Placebo treatment.
in Appendix). Similarly, reduced anti-Hib IgG levels were also
found in the LGG group compared with placebo, with GMCs of
3.96 and 2.35µg/ml, respectively, although this was not signifi-
cant (Figure 3B). Similarly, adjustment for each of the variables
weakened this association but did not affect the conclusions about
differences between LGG and placebo (Tables A1A,B in Appen-
dix). However, LGG supplementation did not have any effect on
total IgG levels in the serum of these infants (Figure 4).
MATERNAL LGG SUPPLEMENTATION WAS ASSOCIATED WITH
INCREASED FREQUENCY OF TT-SPECIFIC Treg IN INFANTS AT
12MONTHS OF AGE
As LGG has been suggested to promote tolerogenic T regula-
tory (Treg) responses, we investigated the effect of maternal LGG
treatment on Treg responses to the vaccine antigen in infants at
12 months of age. There was a significantly higher number and
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FIGURE 3 | Levels of (A) anti-TT IgG and (B) anti-Hib IgG (GMC±95%
CI) for infants in the LGG (N =31) or Placebo (N =30) groups following
TT and Hib immunization. *p<0.05 comparing LGG and Placebo
treatment.
FIGURE 4 | Level of total IgG in the serum of infants (GMC± 95% CI) in
the LGG (N =31) and Placebo (N =30) groups.
percentage of TT-specific CD4+ T cells in infants of LGG-treated
mothers compared to infants of placebo-treated mothers (4563 vs.
3505; p= 0.027; 50.7 vs. 35.6%; p= 0.016) after stimulation with
TT (Figure 5). In addition, there was a non-significant increase
in total Treg numbers following stimulation with TT in infants of
LGG-treated mothers as compared to infants of placebo-treated
mothers (LGG group= 407 vs. placebo group= 305). This was
also observed for Treg within both the proliferating CFSElo popu-
lation of CD4+ T cells (presumed TT-specific Treg; LGG= 40 vs.
placebo= 21) as well as the non-dividing CFSEhi population of
CD4+ T cells (presumed to be naive Treg that lack TCR specificity
for TT; LGG= 362 vs. placebo= 270) (Figure 5). Only TT was
measured for this response as this part of the panel investigated
during the larger PEPS allergy trial as no PBMCs were available
for additional analyses.
Measurement of cytokine responses to TT revealed no signif-
icant differences between infants in the LGG and placebo groups
for any of the cytokines examined (Figure 6). Interestingly never-
theless, levels of TGF-β produced by PBMCs from infants in the
LGG group were noted to be almost two-fold higher than levels of
infants in the placebo group (Figure 6).
DISCUSSION
This study reports that maternal supplementation with the pro-
biotic L. rhamnosus GG (LGG) was able to reduce the levels of
vaccine-specific antibodies in infants at 12 months of age. It was
found that the IgG response to TT and PCV7 vaccines was signifi-
cantly lower amongst infants of mothers treated with LGG during
pregnancy. However no effects on the IgG response to Hib vac-
cine were observed. Moreover, total IgG levels were similar across
the groups, and consistent with previous data (18), suggesting
that maternal LGG may be able to modulate, directly or indi-
rectly, specific immune responses in the infants. This is the first
study to examine this immune-modulating potential of LGG when
administered to mothers during pregnancy and includes a com-
prehensive evaluation of the immune response to a broad range
of vaccine antigens.
In our study, LGG reduced the antibody response to all vac-
cines studied, with significant reductions observed for TT and
four of seven PCV7 serotypes (4, 18C, 19F, and 23F). There was
also a reduced proportion of infants with protective IgG levels
(≥0.35µg/ml) to several PCV7 serotypes at 12 months of age.
The effect of LGG on the anti-TT response was also associated
with increased numbers of TT-specific Treg, although this was not
statistically significant. The higher number of Treg – but not per-
centage of Treg in the CD4+ T cell population – is most likely a
reflection of the significantly higher number and proportion of
CD4+ T cells in the LGG group compared to placebo. These data
suggest that LGG may induce Th1 responses that are transferred to
these allergic infants in early life, consistent with LGG’s reported
effects in allergy involving upregulated TT-specific CD4+ Treg
which may explain the lower TT-specific IgG levels observed in
this study. In addition, the elevated (non-significant) TGF-β levels
in PBMC supernatants from infants in the LGG group also pro-
vide further support for a possible Treg-mediated effect for TT. It
is possible that the relatively small sample size in this study may
have precluded our ability to detect any real differences by LGG.
The infants in this study were part of a larger randomized,
placebo-controlled trial for eczema prevention (termed PEPS) and
were considered “high-risk” for the development of allergic dis-
ease. Maternal LGG supplementation in this study was not able to
prevent the development of eczema in infants by 12 months of age
compared to placebo treatment (15).
However, in this study, more infants had reported eczema or
atopy in the LGG group compared to placebo and it is possible
that the LGG effect on vaccine responses were in part due to their
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FIGURE 5 | Numbers and frequency (%) of CD3+CD4+ T cells,
total CD4+CD25+FoxP3+Treg, dividing (CFSElo), and non-dividing
(CFSEhi)Treg identified in PBMCs isolated from infants in the
LGG (N =31) or Placebo (N =30) groups. PBMCs (1× 106/ml)
were stimulated with TT (1µg/ml) or unstimulated (medium) for
6 days at 37°C and 5% CO2. Bars represent median+ interquartile
range (IQR). Significance determined using the Mann–Whitney
U -test.
allergic status. In allergy, the immune system is dysregulated with
a predominately Th2-biased response characterized by increased
levels of IgE and cytokines such as IL-4 and IL-13 while IgG levels
and Th1 cytokines such as IFN-γ are reduced (19, 20). A shift
toward Th2-based IgE responses in allergy is known to downregu-
late Th1-based IgG levels – which are typically induced following
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FIGURE 6 | Levels of IL-4, IL-6, IL-10, IL-13, IFNγ,TNFα, andTGFβ in PBMC supernatants following stimulation withTT (1µg/ml) or unstimulated
(medium) for 6 days at 37°C and 5% CO2. Bars represent GMC±95% CI.
vaccination – and so it may be possible that the vaccine-specific
responses seen in the LGG group were a result of their allergic sta-
tus rather than the probiotic itself. No differences were observed
in relation to the Th1:Th2 balance between these groups despite a
trend toward higher levels of the regulatory cytokine TGF-β in the
LGG group. However, following adjustment for eczema status and
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atopy, this effect for LGG persisted, indicating that allergic status
did not bias these results. It is therefore likely that the effect of LGG
was related to an induction of maternal tolerogenic responses that
were transferred to the infant. The fact that maternal LGG did not
reduce total IgG levels in the infant provides further support to
the ability of LGG to modulate certain antigen-specific responses.
The IgG response to an unrelated (non-vaccine) antigen was not
undertaken in this study but is expected to be low in this cohort
given the age of the infants and the relative lack of exposure to anti-
gens other than those in the vaccines. This is best illustrated for
pneumococcal vaccination, whereby infants previously given three
doses of PCV7 during infancy produce elevated IgG responses to
vaccine serotypes but not non-vaccine serotypes at 12 months of
age (21). Furthermore, the use of total IgG as a non-vaccine antigen
control for TT-responses has been reported previously (22).
There are several mechanisms by which probiotics mediate
their tolerogenic effects which may help to explain our results
observed. A number of studies have reported that probiotics such
as LGG are able to increase the number and function of allergen-
specific Treg in mice (23) and humans (24). This may occur
through direct cell-cell contact or via the release of regulatory
cytokines such as TGF-β and IL-10 (25–27) and are critical for
the control of immune-mediated diseases (28) and have been
reported to correlate with the amelioration of clinical allergy (29–
31). Maternal supplementation with probiotics has been shown
to induce immunomodulatory effects in infants via cord blood,
breast milk, or indirectly through changes to intestinal microbiota
(32, 33). We recently reported that LGG reduced the levels of TGF-
β and total IgA in breast milk (34) which may explain the lack of
effect against allergic disease. It is possible that the maternal LGG
was transferred to the infants in this study resulting in changes to
the intestinal microbiome. It is now known that the microbiome is
a critical factor in shaping the infant immune system by providing
essential signals that drive healthy immune development (35).
Probiotics have also been increasingly used as a strategy to
restore intestinal dysbiosis that is associated with allergic dis-
ease. Early-life interactions between intestinal microbiota and
the immune system is critical for the development of a healthy
immune system (36). Altered microbiota containing fewer ben-
eficial bacteria are suggested to provide inappropriate signals to
mucosal immune cells leading to aberrant inflammatory responses
and a loss of immune regulation. Studies have reported that prena-
tal and/or postnatal probiotic treatment with various Lactobacillus
and Bifidobacterium species improved microbiota patterns (37,
38). Moreover, data from meta-analyses on the ability of probiotics
to prevent allergic diseases are inconclusive, owing predominately
to the heterogeneity in the study designs and probiotic used (39,
40). However, prenatal probiotic treatment has shown the most
promise in this context (41), suggesting that early-life signals are
important in immune development. It is possible that LGG trans-
fer from mother to infant may explain the immunomodulatory
effect for LGG in this study. Indeed, in the PEPS study, maternal
supplementation with LGG increased the numbers of the ben-
eficial bacteria B. longum (42) which are important for healthy
immune development. Investigations are currently ongoing as to
whether the presence of B. longum influenced the Th1:Th2 balance
in these infants at 12 months of age. It is possible that such early-life
influences on microbiota may impact on the immune response to
vaccines, particularly in the first 6 months of life. Indeed, it is
now recognized that the intestinal microbiome should be consid-
ered when developing vaccines specific for certain geographical
regions and populations since vaccine efficacy may vary based on
the microbial composition of the gastrointestinal system (43).
More recently, the use of probiotics as novel vaccine adjuvants
has been investigated (44). Infants treated with LGG at 2–5 months
of age had an elevated (but not significant) serum IgA and IgM
response following an oral rotavirus vaccine, as well as significantly
higher numbers of rotavirus-specific IgM secreting cells compared
to placebo (13). LGG was also shown to enhance neutralizing
antibody titers as well as serum poliovirus-specific IgG and IgA
in adults immunized with the trivalent oral polio vaccine (OPV)
compared to placebo (45). In another study, a greater proportion
of LGG-treated adults had higher numbers of Typhi-specific IgA
secreting cells (ASCs) following oral S. typhi Ty21a immunization
despite no differences in the specific antibody response (46). In
addition, probiotics have been shown to elicit adjuvant properties
following immunization with other vaccines such as influenza (14,
47, 48), Hep B (49), and polio (50).
The identification of novel adjuvants that can be administered
in early-life would provide a substantial benefit in settings of high
infectious disease burden. The contribution of the pneumococcus,
Hib, and tetanus to neonatal and infant mortality is considerable,
with more than two million deaths each year (51, 52). Further-
more, in developing countries, vaccine delivery is a significant
problem where access to complete vaccination schedules is limited
or where drop-out rates are high (53). Therefore probiotics poten-
tially offer substantial advantages as vaccine adjuvants in terms
of safety, ease of administration and their demonstrated ability to
enhance immune responses. The reduced proportion of protective
antibody levels in the LGG group may pose a theoretical increased
risk of disease susceptibility which would be particularly impor-
tant in high burden of disease settings. However, as this study was
not designed to specifically address the effect of probiotics on vac-
cine responses, further large scale randomized trials are required
to fully evaluate this effect.
A major strength of this study is the comprehensive evaluation
of LGG’s capacity to modulate infant vaccine responses follow-
ing maternal supplementation, involving pneumococcal, Hib, and
TT-specific immune responses. In addition, this is one of the first
studies to describe the adjuvant effect of probiotics for PCV7
using WHO-based assays. However, several limitations need to
be addressed. This is a relatively small cohort and so caution must
be applied when considering the results of this study. The effect of
multiple comparison testing cannot be excluded and in this study
was not performed due to the small sample size. Furthermore, this
study may not be adequately powered to detect a beneficial impact
of LGG on infant vaccine responses given the primary outcome was
clinical allergy at 12 months of age. Also, maternal LGG supple-
mentation may not be as effective as a combined prenatal/postnatal
or postnatal alone approach for examination of the infant immune
response to vaccines as has been shown for studies of allergic dis-
ease (10). Moreover, all vaccinations were administered as part
of the 3-dose National Immunization Program in Australia which
might not be optimal to detect any differences in these responses, as
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all recipients would be expected to respond robustly to this sched-
ule (54). Examination of earlier post-vaccination time-points may
have potentially revealed important differences by LGG. It is also
possible that probiotics other than LGG may be more beneficial
in this setting since it is known that the activities of probiotics are
dependent on the species and strain used (18). Subsequent stud-
ies in a larger healthy cohort will be important in understanding
the potential benefits of probiotics in modulating vaccine-specific
immune responses during early-life.
CONCLUSION
The probiotic LGG was found to reduce the antibody levels specific
for TT, PCV7, and Hib but not total IgG in infants at 12 months
of age who were part of a maternal supplementation trial for the
prevention of allergic disease. These results suggest that this probi-
otic may not be beneficial in relation to improving vaccine-specific
responses in these infants. Various factors may have impacted on
this response such as the nature of the cohort, timing of probiotic
administration, or the probiotic itself. Therefore additional stud-
ies that are designed to specifically address these questions will be
of significant interest, particularly in settings of high infectious
disease burden and where access to complete vaccine schedules is
limited.
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APPENDIX
Table A1A | Summary of the vaccine-specific IgG responses following adjustment for eczema and atopy.
Adjusted
Vaccine Unadjusteda IgE-eczema (at 12 months) IgE-eczema (ever) Atopy
PCV7–4 0.47 (0.21); p=0.027 0.51 (0.21); p=0.019 0.50 (0.21); p=0.022 0.50 (0.21); p=0.023
PCV7–6B 0.43 (0.20); p=0.040 0.48 (0.21); p=0.025 0.50 (0.21); p=0.020 0.45 (0.21); p=0.040
PCV7–9V 0.39 (0.22); p=0.085 0.45 (0.23); p=0.055 0.44 (0.23); p=0.060 0.47 (0.23); p=0.040
PCV7–14 0.19 (0.23); p=0.413 0.23 (0.24); p=0.344 0.24 (0.24); p=0.316 0.23 (0.24); p=0.337
PCV7–18C 0.48 (0.22); p=0.032 0.51 (0.22); p=0.027 0.52 (0.22); p=0.024 0.53 (0.22); p=0.021
PCV7–19F 0.47 (0.22); p=0.041 0.47 (0.23); p=0.047 0.48 (0.23); p=0.045 0.47 (0.23); p=0.047
PCV7–23F 0.54 (0.22); p=0.019 0.57 (0.23); p=0.017 0.58 (0.23); p=0.015 0.54 (0.23); p=0.022
Tetanus toxoid 0.60 (0.289); p=0.042 0.60 (0.30); p=0.052 0.63 (0.30); p=0.039 0.64 (0.30); p=0.037
Hib 0.56 (0.44); p=0.212 0.50 (0.48); p=0.306 0.51 (0.48); p=0.293 0.57 (0.47); p=0.234
Data represents the regression coefficient and standard errors in brackets. Regression coefficient refers to the group as a predictor for each of the outcome measures
where the baseline for comparison is the LGG group (n=31).
For example, considering PCV7–4 (coefficient of 0.47 in the unadjusted analysis) refers that the mean response for PCV7–4 in the control group (Placebo) is 0.49
times higher than the mean response for the LGG group.
aUnadjusted analysis after removing missing data for eczema and atopy variables (N=30 LGG; N=30 Placebo). This refers to the analysis between the LGG and
placebo groups after removal of vaccine immune responses for the one infant where the eczema/atopy status was not available.
Table A1B | Summary of the vaccine-specific IgG responses following adjustment for yogurt intake.
Yogurt intake
Vaccine Unadjusteda Adjusted
PCV7–4 0.66 (0.22); p=0.005 0.56 (0.22); p=0.015
PCV7–6B 0.28 (0.23); p=0.229 0.20 (0.23); p=0.390
PCV7–9V 0.56 (0.24); p=0.025 0.53 (0.25); p=0.041
PCV7–14 0.32 (0.25); p=0.200 0.31 (0.26); p=0.229
PCV7–18C 0.63 (0.24); p=0.011 0.59 (0.24); p=0.019
PCV7–19F 0.56 (0.24); p=0.024 0.52 (0.25); p=0.042
PCV7–23F 0.71 (0.24); p=0.005 0.67 (0.25); p=0.009
Tetanus toxoid 0.64 (0.33); p=0.055 0.68 (0.34); p=0.047
Hib 0.50 (0.46); p=0.286 0.35 (0.48); p=0.463
Data represents the regression coefficient and standard errors in brackets.
aUnadjusted analysis after removing missing data for yogurt intake (N= 25 LGG; N=26 Placebo).
Table A2A | Summary of the PCV7 serotype-specific IgG responses ≥0.35µg/ml following adjustment for eczema and atopy.
Adjusted
Vaccine Unadjusteda IgE-eczema (at 12 months) IgE-eczema (ever) Atopy
PCV7–4 3.29 (1.08, 9.95); p=0.035 3.27 (1.05, 10.19); p=0.041 3.30 (1.09, 10.00); p=0.035 3.47 (1.10, 10.96); p=0.034
PCV7–6B 2.32 (0.72, 7.41); p=0.157 3.04 (0.89, 10.35); p=0.075 2.36 (0.73, 7.61); p=0.149 2.43 (0.73, 8.09); p=0.147
PCV7–9V 3.50 (1.11, 11.02); p=0.032 4.07 (1.23, 13.49); p=0.022 3.62 (1.14, 11.51); p=0.030 4.27 (1.26, 14.43); p=0.019
PCV7–14 NA NA NA NA
PCV7–18C 2.41 (0.82, 7.10); p=0.111 2.30 (0.76, 6.96); p=0.142 2.44 (0.82, 7.23); p=0.107 2.93 (0.92, 9.35); p=0.069
PCV7–19F 4.46 (0.47, 42.51); p=0.194 4.96 (0.50, 48.92); p=0.170 4.48 (0.47, 42.76); p=0.192 4.56 (0.46, 45.46); p=0.196
PCV7–23F 5.21 (1.28; 21.24); p=0.021 5.25 (1.25, 22.03); p=0.024 5.21 (1.28, 21.24); p=0.021 4.67 (1.12, 19.55); p=0.035
Data represents the Odds Ratio and 95% confidence intervals; NA, not assessed due to co-linearity issues.
aUnadjusted analysis after removing missing data for eczema and atopy variables (N=30 LGG; N=30 Placebo).
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Table A2B | Summary of the PCV7 serotype-specific IgG responses ≥0.35µg/ml following adjustment for yogurt intake.
Yogurt intake
Vaccine Unadjusteda Adjusted
PCV7–4 4.07 (1.25, 13.24); p=0.020 3.63 (1.09, 12.10); p=0.036
PCV7–6B 1.98 (0.55, 7.16); p=0.300 1.92 (0.51, 7.16); p=0.333
PCV7–9V 5.35 (1.52, 18.75); p=0.009 5.36 (1.48, 19.36); p=0.010
PCV7–14 NA NA
PCV7–18C 2.71 (0.82, 9.00); p=0.103 2.75 (0.80, 9.39); p=0.107
PCV7–19F 4.76 (0.49, 45.95); p=0.177 3.60 (0.35, 37.09); p=0.281
PCV7–23F 6.02 (1.43, 25.40); p=0.014 5.74 (1.33, 24.79); p=0.019
Data represents the Odds Ratio and 95% confidence intervals; NA, not assessed due to co-linearity issues.
aUnadjusted analysis after removing missing data for yogurt intake (N=25 LGG; N=26 Placebo).
Table A3A | Summary of the PCV7 serotype-specific IgG responses ≥1.0µg/ml following adjustment for eczema and atopy.
Adjusted
Vaccine Unadjusteda IgE-eczema (at 12 months) IgE-eczema (ever) Atopy
PCV7–4 1.30 (0.31, 5.40); p=0.718 1.30 (0.30, 5.64); p=0.726 1.28 (0.31, 5.36); p=0.731 1.50 (0.34, 6.65); p=0.591
PCV7–6B 2.32 (0.72, 7.41); p=0.157 2.21 (0.67, 7.27); p=0.193 2.32 (0.72, 7.41); p=0.157 2.24 (0.68, 7.40); p=0.187
PCV7–9V 1.22 (0.36, 4.17); p=0.754 1.23 (0.35, 4.36); p=0.752 1.20 (0.35, 4.14); p=0.776 1.66 (0.44, 6.25); p=0.456
PCV7–14 1.25 (0.34, 4.64); p=0.739 1.20 (0.31, 4.63); p=0.794 1.24 (0.33, 4.62); p=0.746 1.25 (0.32, 4.82); p=0.751
PCV7–18C 1.56 (0.24, 10.05); p=0.643 NA NA NA
PCV7–19F 2.62 (0.92, 7.46); p=0.072 2.32 (0.79, 6.79); p=0.125 2.61 (0.92, 7.45); p=0.073 2.49 (0.85, 7.32); p=0.096
PCV7–23F 2.00 (0.62, 6.46); p=0.247 2.16 (0.64, 7.32); p=0.217 1.98 (0.61, 6.47); p=0.256 2.19 (0.64, 7.43); p=0.210
Data represents the Odds Ratio and 95% confidence intervals; NA, not assessed due to co-linearity issues.
aUnadjusted analysis after removing missing data for eczema and atopy variables (N=30 LGG; N=30 Placebo).
Table A3B | Summary of the PCV7 serotype-specific IgG responses ≥1.0µg/ml following adjustment for yogurt intake.
Yogurt intake
Vaccine Unadjusteda Adjusted
PCV7–4 2.74 (0.48, 15.65); p=0.257 2.17 (0.35, 13.39); p=0.404
PCV7–6B 1.41 (0.41, 4.86); p=0.589 1.11 (0.30, 4.11); p=0.873
PCV7–9V 1.47 (0.40, 5.45); p=0.561 1.20 (0.31, 4.68); p=0.797
PCV7–14 1.33 (0.35, 5.06); p=0.679 1.33 (0.34, 5.25); p=0.683
PCV7–18C 0.96 (0.12, 7.38); p=0.967 0.80 (0.10, 6.50); p=0.834
PCV7–19F 2.57 (0.80, 8.23); p=0.112 2.20 (0.66, 7.30); p=0.199
PCV7–23F 2.78 (0.73, 10.62); p=0.135 2.31 (0.57, 9.29); p=0.238
Data represents the Odds Ratio and 95% confidence intervals; NA, not assessed due to co-linearity issues.
aUnadjusted analysis after removing missing data for yogurt intake (N=25 LGG; N=26 Placebo).
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